Skip to main content

Teleflex Value Stock - Dividend - Research Selection

Teleflex

ISIN: US8793691069 , WKN: 855853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Needham Upgrades Teleflex (TFX)

2026-01-27

Sector Update: Health Care Stocks Retreat Late Afternoon

2026-01-08
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 0.7% and t

Teleflex Announces Leadership Transition

2026-01-08
Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company’s Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who d

3 Unprofitable Stocks We Steer Clear Of

2026-01-05
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Is Teleflex Attractively Priced After Sharp Five Year Slide and DCF Concerns in 2025

2025-12-22
Wondering if Teleflex is a beaten down opportunity or a value trap at today’s price? Let us walk through what the numbers are really saying about the stock. After sliding 3.8% over the last week, Teleflex is still up 10.6% over the past month, but its year to date return of around -31.9% and one year return of -30.9% show investors are still cautious after a multi year drawdown of about -69% over five years. Recent headlines have focused on Teleflex’s portfolio of interventional and surgical...

Teleflex (TFX): Reassessing Valuation After Recent Share Price Pullback and Mixed Long-Term Returns

2025-12-22
Teleflex (TFX) has quietly become a talking point after another choppy week for medtech names, with the stock drifting lower over the past week even as the past month’s performance turned positive. See our latest analysis for Teleflex. That recent pullback sits against a much tougher backdrop, with the year to date share price return down sharply and multi year total shareholder returns still deeply negative. This suggests momentum is only tentatively stabilising despite solid underlying...

Truist Securities Maintains Teleflex (TFX) Hold Recommendation

2025-12-19

Should You Retain Teleflex Stock in Your Portfolio Now?

2025-12-17
TFX's UroLift expansion and Barrigel traction support long-term growth, but high debt and FX headwinds keep the stock under pressure.

Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?

2025-12-11
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.

Wells Fargo Maintains Teleflex (TFX) Equal-Weight Recommendation

2025-12-10